Europe Infectious Disease Diagnostics Market - Country-Wise Analysis: Focus on Product, Testing Location, Infectious Disease Type, Infection Type, Technology, and End User - Analysis and Forecast, 2021-2031
Market Report Coverage - Europe Infectious Disease Diagnostics
Market Segmentation
- Product (system, kits and reagents, and software)
- Testing location (laboratory testing and point-of-care testing)
- Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)
- Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)
- Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)
- End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
- Europe-5 - Germany, U.K., France, Italy and Spain
- Nordic- Denmark, Sweden, Norway and Finland
- Baltic- Estonia, Lithuania and Latvia
- Rest-of-Europe
- Increasing Prevalence of Infectious Diseases
- Technological Innovation Resulting in Market Pull
- Significant External Funding Supporting Market Growth Market Challenges
- Uncertain Reimbursement Scenario
- Lack of High Complexity Testing Centers
- Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
- Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations
- Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests
Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer Inc., Hologic Inc. (Mobidiag Ltd.), Abacus Diagnostica Oy, Novacyt Group, Biocartis
Key Questions Answered in this Report:
How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
Product (system, kits and reagents, and software)
Testing location (laboratory testing and point-of-care testing)
Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)
Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)
Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)
End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
Region (EU-5, Baltic, Nordic, and Rest-of-Europe)
What are the major market drivers, challenges, and opportunities in the Europe infectious disease diagnostics market?
What are the underlying structures resulting in the emerging trends within the Europe infectious disease diagnostics market?
How is each segment of the Europe infectious disease diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
What are the key developmental strategies implemented by the major players to sustain in the competitive market?
What are the key regulatory implications in developed and developing regions for molecular diagnostics?
Who are the leading players with significant offerings to the Europe infectious disease diagnostics market? What is the current market dominance for each of these leading players?
What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which infectious disease product type is anticipated to have the most promising growth?
What are the key applications in the Europe infectious disease diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
What are the major technologies that are employed in the Europe infectious disease diagnostics market? Which is the dominating technology?
Who are the primary end users of the Europe infectious disease diagnostics market? Which is the fastest-growing end-user segment in the Europe infectious disease diagnostics market?
Who are the key manufacturers in the Europe infectious disease diagnostics market, and what are their contributions? Also, what is the growth potential of each major infectious disease diagnostics manufacturer?
What is the scope of the Europe infectious disease diagnostics market in the EU’5, Baltic, and Nordic regions? Which infectious disease diagnostics product and end user dominate these regions?
What are the emerging trends in the Europe infectious disease diagnostics market? How are these trends revolutionizing the diagnostic procedure?
Which technologies are anticipated to break through the current infectious diseases diagnostic regime?
Which companies are anticipated to be highly disruptive in the future and why?
What are the regulatory procedures required to unify the approval process for emerging infectious disease diagnostics? How will these enhance the reimbursement scenario?
What are the gaps in regularizing optimum infectious disease diagnostics adoption in regular healthcare routines? How are these gaps being tackled?
Market Overview
The use of infectious disease diagnostics kits, assays, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives. The increasing investments by healthcare companies to meet industry demand and the growing adoption of infectious disease diagnostics kits, tubes, and reagents among major end users are major factors propelling the growth of the Europe infectious disease diagnostics market. The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
Competitive Landscape
The Europe infectious disease diagnostics market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for infectious disease diagnostics from different product types. Key market players of the Europe infectious disease diagnostics market witnessed product launch and approval, business funding, and synergistic activities from January 2018 to March 2022. The inclination of companies toward product launches suggests that companies are constantly bringing new products to the market to test viral and bacterial infections, which is primarily attributed to an increase in demand for kits and assays by end users.
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Markets
- 1.1 Product Definition
- 1.1.1 Definitions
- 1.1.2 Inclusion and Exclusion
- 1.2 Market Overview
- 1.3 Significant Technologies in Infectious Disease Diagnostics
- 1.4 Classification of Infectious Disease Diagnostics
- 1.5 Europe Footprint
- 1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.2.1 Increasing Prevalence of Infectious Diseases
- 1.6.2.2 Technological Innovation Resulting in Market Pull
- 1.6.2.3 Significant External Funding Supporting Market Growth
- 1.6.3 Market Restraints
- 1.6.3.1 Uncertain Reimbursement Scenario
- 1.6.3.2 Lack of High Complexity Testing Centers
- 1.6.3.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
- 1.6.4 Market Opportunities
- 1.6.4.1 Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations
- 1.6.4.2 Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests
- 1.7 COVID-19 Impact on Europe Infectious Disease Diagnostics Market
- 1.7.1 COVID-19 Impact on Infectious Disease Diagnostics Market Size
- 1.7.2 Realistic Growth Scenario
- 1.7.3 Optimistic Growth Scenario
- 1.7.4 Disruption in Europe Infectious Disease Diagnostics Market Due to COVID-19
- 1.8 Competitive Landscape
- 1.8.1 Acquisitions
- 1.8.2 Synergistic Activities
- 1.8.3 Product Launches and Approvals
- 1.8.4 Business Expansion Activities
- 1.8.5 Market-Share Analysis (by Company)
- 1.8.6 Growth-Share Analysis (by Technology)
- 1.9 Industry Insights
- 1.9.1 Legal Requirements and Framework in Europe
- 2 Products
- 2.1 Overview
- 2.1.1 System
- 2.1.2 Kits and Reagents
- 2.1.3 Software
- 3 Testing Location
- 3.1 Overview
- 3.1.1 Laboratory Testing
- 3.1.2 Point-of-Care Testing
- 4 Technology
- 4.1 Overview
- 4.1.1 Polymerase Chain Reaction (PCR)
- 4.1.1.1 Real-Time PCR (RT-PCR)
- 4.1.1.2 Digital PCR (d-PCR)
- 4.1.2 Next-Generation Sequencing
- 4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 4.1.4 Microarray
- 4.1.5 In-Situ Hybridization (ISH)
- 4.1.6 Immunodiagnostics
- 4.1.7 Other Technologies
- 5 Infectious Disease Type
- 5.1 Overview
- 5.1.1 Bacterial Infectious Diseases
- 5.1.2 Viral Infectious Diseases
- 5.1.3 Fungal Infectious Diseases
- 5.1.4 Other Infectious Diseases
- 6 Infection Type
- 6.1 Overview
- 6.1.1 Respiratory Infections
- 6.1.1.1 COVID-19 Infection
- 6.1.1.2 Influenza A and B
- 6.1.1.3 Respiratory Syncytial Virus
- 6.1.1.4 Mycoplasma Infections
- 6.1.1.5 Pertussis Infections
- 6.1.1.6 Other Respiratory Infections
- 6.1.2 Hospital-Acquired Infections (HAIs)
- 6.1.3 Sexually Transmitted Infections (STIs)
- 6.1.3.1 Hepatitis B
- 6.1.3.2 HIV-AIDS
- 6.1.3.3 Human Papillomavirus (HPV)
- 6.1.3.4 Neisseria Gonorrhea
- 6.1.3.5 Other STIs
- 6.1.4 Other Infections
- 7 End User
- 7.1 Overview
- 7.1.1 Hospitals
- 7.1.1.1 Hospitals (by Respiratory Infections)
- 7.1.1.1.1 Hospitals (Influenza A and B)
- 7.1.1.1.2 Hospitals (COVID-19 Infection)
- 7.1.1.1.3 Hospitals (Respiratory Syncytial Virus (RSV))
- 7.1.1.1.4 Hospitals (Mycoplasma Infections)
- 7.1.1.1.5 Hospitals (Pertussis Infections)
- 7.1.1.1.6 Hospitals (Other Respiratory Infections)
- 7.1.1.2 Hospitals (by Sexually Transmitted Infections (STIs))
- 7.1.1.2.1 Hospitals (Hepatitis B)
- 7.1.1.2.2 Hospitals (HIV-AIDS)
- 7.1.1.2.3 Hospitals (HPV)
- 7.1.1.2.4 Hospitals (Neisseria Gonorrhea)
- 7.1.1.2.5 Hospitals (Other STIs)
- 7.1.2 Diagnostic Centers
- 7.1.2.1 Diagnostic Centers (by Respiratory Infections)
- 7.1.2.1.1 Diagnostic Centers (Influenza A and B)
- 7.1.2.1.2 Diagnostic Centers (COVID-19 Infection)
- 7.1.2.1.3 Diagnostic Centers (Respiratory Syncytial Virus (RSV))
- 7.1.2.1.4 Diagnostic Centers (Mycoplasma Infections)
- 7.1.2.1.5 Diagnostic Centers (Pertussis Infections)
- 7.1.2.1.6 Diagnostic Centers (Other Respiratory Infections)
- 7.1.2.2 Diagnostic Centers (by Sexually Transmitted Infections (STIs))
- 7.1.2.2.1 Diagnostic Centers (Hepatitis B)
- 7.1.2.2.2 Diagnostic Centers (HIV-AIDS)
- 7.1.2.2.3 Diagnostic Centers (HPV)
- 7.1.2.2.4 Diagnostic Centers (Neisseria Gonorrhea)
- 7.1.2.2.5 Diagnostic Centers (Other STIs)
- 7.1.3 Out-Patient Clinics/General Practitioners
- 7.1.3.1 Out-Patient Clinics/General Practitioners (by Respiratory Infections)
- 7.1.3.1.1 Out-Patient Clinics/General Practitioners (Influenza A and B)
- 7.1.3.1.2 Out-Patient Clinics/General Practitioners (COVID-19 Infection)
- 7.1.3.1.3 Out-Patient Clinics/General Practitioners (Respiratory Syncytial Virus (RSV))
- 7.1.3.1.4 Out-Patient Clinics/General Practitioners (Mycoplasma Infections)
- 7.1.3.1.5 Out-Patient Clinics/General Practitioners (Pertussis Infections)
- 7.1.3.1.6 Out-Patient Clinics/General Practitioners (Other Respiratory Infections)
- 7.1.3.2 Out-Patient Clinics/General Practitioners (by Sexually Transmitted Infections (STIs))
- 7.1.3.2.1 Out-Patient Clinics/General Practitioners (Hepatitis B)
- 7.1.3.2.2 Out-Patient Clinics/General Practitioners (HIV-AIDS)
- 7.1.3.2.3 Out-Patient Clinics/General Practitioners (HPV)
- 7.1.3.2.4 Out-Patient Clinics/General Practitioners (Neisseria Gonorrhea)
- 7.1.3.2.5 Out-Patient Clinics/General Practitioners (Other STIs)
- 7.1.4 Research Laboratories
- 7.1.4.1 Research Laboratories (by Respiratory Infections)
- 7.1.4.1.1 Research Laboratories (Influenza A and B)
- 7.1.4.1.2 Research Laboratories (COVID-19 Infection)
- 7.1.4.1.3 Research Laboratories (Respiratory Syncytial Virus (RSV))
- 7.1.4.1.4 Research Laboratories (Mycoplasma Infections)
- 7.1.4.1.5 Research Laboratories (Pertussis Infections)
- 7.1.4.1.6 Research Laboratories (Other Respiratory Infections)
- 7.1.4.2 Research Laboratories (by Sexually Transmitted Infections (STIs))
- 7.1.4.2.1 Research Laboratories (Hepatitis B)
- 7.1.4.2.2 Research Laboratories (HIV-AIDS)
- 7.1.4.2.3 Research Laboratories (HPV)
- 7.1.4.2.4 Research Laboratories (Neisseria Gonorrhea)
- 7.1.4.2.5 Research Laboratories (Other STIs)
- 7.1.5 Other End Users
- 8 Regions
- 8.1 Overview
- 8.2 Europe-5
- 8.2.1 Europe Infectious Disease Diagnostics Market (by Infectious Disease Type)
- 8.2.2 Germany
- 8.2.3 U.K.
- 8.2.4 France
- 8.2.5 Italy
- 8.2.6 Spain
- 8.3 Baltic
- 8.3.1 Estonia
- 8.3.2 Lithuania
- 8.3.3 Latvia
- 8.4 Nordic
- 8.4.1 Denmark
- 8.4.2 Sweden
- 8.4.3 Norway
- 8.4.4 Finland
- 8.5 Rest-of- Europe
- 9 Company Profiles
- 9.1 Overview
- 9.2 Abbott
- 9.2.1 Company Overview
- 9.2.2 Role of Abbott in the Europe Infectious Disease Diagnostics Market
- 9.2.3 Key Competitors of the Company
- 9.2.4 Key Customers of the Company
- 9.2.5 Corporate Strategies
- 9.2.6 Business Strategies
- 9.2.7 Financials
- 9.2.8 Key Insights about the Financial Health of the Company
- 9.2.9 SWOT Analysis
- 9.3 Agilent Technologies, Inc.
- 9.3.1 Company Overview
- 9.3.2 Role of Agilent Technologies, Inc. in the Europe Infectious Disease Diagnostics Market
- 9.3.3 Key Competitors of the Company
- 9.3.4 Key Customers of the Company
- 9.3.5 Corporate Strategies
- 9.3.6 Business Strategies
- 9.3.7 Financials
- 9.3.8 Key Insights about the Financial of the Company
- 9.3.9 SWOT Analysis
- 9.4 Becton, Dickinson and Company (BD)
- 9.4.1 Company Overview
- 9.4.2 Role of Becton, Dickinson and Company (BD) in the Europe Infectious Disease Diagnostics Market
- 9.4.3 Key Competitors of the Company
- 9.4.4 Key Customers of the Company
- 9.4.5 Corporate Strategies
- 9.4.6 Business Strategies
- 9.4.7 Financials
- 9.4.8 Key Insights about the Financial Health of the Company
- 9.4.9 SWOT Analysis
- 9.5 bioMérieux SA
- 9.5.1 Company Overview
- 9.5.2 Role of bioMérieux SA in the Europe Infectious Disease Diagnostics Market
- 9.5.3 Key Competitors of the Company
- 9.5.4 Key Customers of the Company
- 9.5.5 Business Strategies
- 9.5.6 Financials
- 9.5.7 Key Insights about the Financial Health of the Company
- 9.5.8 SWOT Analysis
- 9.6 Bio-Rad Laboratories, Inc.
- 9.6.1 Company Overview
- 9.6.2 Role of Bio-Rad Laboratories, Inc. in the Europe Infectious Disease Diagnostics Market
- 9.6.3 Key Competitors of the Company
- 9.6.4 Key Customers of the Company
- 9.6.5 Corporate Strategies
- 9.6.6 Business Strategies
- 9.6.7 Financials
- 9.6.8 Key Insights about the Financial Health of the Company
- 9.6.9 SWOT Analysis
- 9.7 Danaher
- 9.7.1 Company Overview
- 9.7.2 Role of Danaher in the Europe Infectious Disease Diagnostics Market
- 9.7.3 Key Competitors of the Company
- 9.7.4 Key Customers of the Company
- 9.7.5 Corporate Strategies
- 9.7.6 Business Strategies
- 9.7.7 Financials
- 9.7.8 Key Insights about the Financial Health of the Company
- 9.7.9 SWOT Analysis
- 9.8 F. Hoffmann-La Roche Ltd
- 9.8.1 Company Overview
- 9.8.2 Role of F. Hoffmann-La Roche Ltd in the Europe Infectious Disease Diagnostics Market
- 9.8.3 Key Competitors of the Company
- 9.8.4 Key Customers of the Company
- 9.8.5 Business Strategies
- 9.8.6 Financials
- 9.8.7 Key Insights about the Financial Health of the Company
- 9.8.8 SWOT Analysis
- 9.9 Illumina, Inc.
- 9.9.1 Company Overview
- 9.9.2 Role of Illumina, Inc. in the Europe Infectious Disease Diagnostics Market
- 9.9.3 Key Competitors of the Company
- 9.9.4 Key Customers of the Company
- 9.9.5 Financials
- 9.9.6 Key Insights about the Financial Health of the Company
- 9.9.7 SWOT Analysis
- 9.1 QIAGEN N.V.
- 9.10.1 Company Overview
- 9.10.2 Role of QIAGEN N.V. in the Europe Infectious Disease Diagnostics Market
- 9.10.3 Key Competitors of the Company
- 9.10.4 Key Customers of the Company
- 9.10.5 Corporate Strategies
- 9.10.6 Business Strategies
- 9.10.7 Financials
- 9.10.8 Key Insights about the Financial Health of the Company
- 9.10.9 SWOT Analysis
- 9.11 Siemens Healthcare GmbH
- 9.11.1 Company Overview
- 9.11.2 Role of Siemens Healthcare GmbH in the Europe Infectious Disease Diagnostics Market
- 9.11.3 Key Competitors of the Company
- 9.11.4 Key Customers of the Company
- 9.11.5 Business Strategies
- 9.11.6 Financials
- 9.11.7 Key Insights about the Financial Health of the Company
- 9.11.8 SWOT Analysis
- 9.12 Thermo Fisher Scientific Inc.
- 9.12.1 Company Overview
- 9.12.2 Role of Thermo Fisher Scientific Inc. in the Europe Infectious Disease Diagnostics Market
- 9.12.3 Key Competitors of the Company
- 9.12.4 Key Customers of the Company
- 9.12.5 Business Strategies
- 9.12.6 Financials
- 9.12.7 Key Insights about the Financial Health of the Company
- 9.12.8 SWOT Analysis
- 9.13 PerkinElmer Inc.
- 9.13.1 Company Overview
- 9.13.2 Role of PerkinElmer Inc. in the Europe Infectious Disease Diagnostics Market
- 9.13.3 Key Competitors of the Company
- 9.13.4 Key Customers of the Company
- 9.13.5 Financials
- 9.13.6 Key Insights about the Financial Health of the Company
- 9.13.7 SWOT Analysis
- 9.14 Hologic Inc. (Mobidiag Ltd.)
- 9.14.1 Company Overview
- 9.14.2 Role of Hologic Inc. (Mobidiag Ltd.) in the Europe Infectious Disease Diagnostics Market
- 9.14.3 Key Competitors of the Company
- 9.14.4 Key Customers of the Company
- 9.14.5 Financials
- 9.14.6 Key Insights about the Financial Health of the Company
- 9.14.7 SWOT Analysis
- Emerging Companies
- 9.15 Abacus Diagnostica Oy
- 9.15.1 Company Overview
- 9.15.2 Role of Abacus Diagnostica Oy in the Europe Infectious Disease Diagnostics Market
- 9.15.3 Key Competitors of the Company
- 9.15.4 Key Customers of the Company
- 9.15.5 Business Strategies
- 9.15.6 SWOT Analysis
- 9.16 Novacyt Group.
- 9.16.1 Company Overview
- 9.16.2 Role of Novacyt Group. in the Europe Infectious Disease Diagnostics Market
- 9.16.3 Key Competitors of the Company
- 9.16.4 Key Customers of the Company
- 9.16.5 Business Strategies
- 9.16.6 Financials
- 9.16.7 Key Insights about the Financial Health of the Company
- 9.16.8 SWOT Analysis
- 9.17 Biocartis
- 9.17.1 Company Overview
- 9.17.2 Role of Biocartis in the Europe Infectious Disease Diagnostics Market
- 9.17.3 Key Competitors of the Company
- 9.17.4 Key Customers of the Company
- 9.17.5 Business Strategies
- 9.17.6 SWOT Analysis
- List of Figures
- Figure 1: Distribution of Chronic Lower Respiratory Diseases
- Figure 2: Europe Infectious Disease Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020-2031
- Figure 3: Europe Infectious Disease Diagnostics Market Dynamics
- Figure 4: Share of Key Market Strategies and Developments, January 2018-March 2022
- Figure 5: Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 6: Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 Vs. 2031
- Figure 7: Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 Vs. 2031
- Figure 8: Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
- Figure 9: Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 Vs. 2031
- Figure 10: Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 Vs. 2031
- Figure 11: Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 Vs. 2031
- Figure 12: Europe Infectious Disease Diagnostics Market: Research Methodology
- Figure 13: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 14: Top-Down Approach (Segment-Wise Analysis)
- Figure 15: Europe Infectious Disease Diagnostics Market Segmentation
- Figure 16: Role of Infectious Disease Diagnostics in Healthcare
- Figure 17: Classification of Europe Infectious Disease Diagnostics
- Figure 18: Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 19: Europe Infectious Disease Diagnostics Market Dynamics
- Figure 20: Distribution of Chronic Lower Respiratory Diseases
- Figure 21: Impact of COVID-19 on Europe Infectious Disease Diagnostics Market
- Figure 22: Europe Infectious Disease Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
- Figure 23: Europe Infectious Disease Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
- Figure 24: COVID-19 Impact Analysis of Europe Infectious Disease Diagnostics Market, 2019-2025
- Figure 25: Share of Key Developments and Strategies, January 2018–March 2022
- Figure 26: Share of Acquisitions (by Company), January 2018-March 2022
- Figure 27: Share of Synergistic Activities (by Company), January 2018-March 2022
- Figure 28: Share of Product Launches and Approvals (by Company), January 2018-March 2022
- Figure 29: Share of Business Expansion Activities (by Company), January 2018-March 2022
- Figure 30: Market-Share Analysis for Europe Infectious Disease Diagnostics Market, $Million, 2019 and 2020
- Figure 31: Growth-Share Analysis of Europe Infectious Disease Diagnostics Market (by Technology), 2020-2031
- Figure 32: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
- Figure 33: Share of Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 and 2031
- Figure 34: Europe Infectious Disease Diagnostics Market (System), $Million, 2020-2031
- Figure 35: General Workflow of a Molecular Diagnostic Kit
- Figure 36: Europe Infectious Disease Diagnostics Market (Kits and Reagents), $Million, 2020-2031
- Figure 37: Aspects of Software Development
- Figure 38: Europe Infectious Disease Diagnostics Market (Software), $Million, 2020-2031
- Figure 39: Europe Infectious Disease Diagnostics Market (by Testing Location)
- Figure 40: Share of Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 and 2031
- Figure 41: Europe Infectious Disease Diagnostics Market (Laboratory Testing), $Million, 2020-2031
- Figure 42: Europe Infectious Disease Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
- Figure 43: Europe Infectious Disease Diagnostics Market (by Technology)
- Figure 44: Share of Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 and 2031
- Figure 45: Europe Infectious Disease Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
- Figure 46: Europe Infectious Disease Diagnostics Market (Real-Time PCR (RT-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031
- Figure 47: Europe Infectious Disease Diagnostics Market (Digital PCR (d-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031
- Figure 48: Europe Infectious Disease Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
- Figure 49: Europe Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
- Figure 50: Europe Infectious Disease Diagnostics Market (Microarray), $Million, 2020-2031
- Figure 51: Europe Infectious Disease Diagnostics Market (In-Situ Hybridization (ISH)), $Million, 2020-2031
- Figure 52: Europe Infectious Disease Diagnostics Market (Immunodiagnostics), $Million, 2020-2031
- Figure 53: Europe Infectious Disease Diagnostics Market (Other Technologies), $Million, 2020-2031
- Figure 54: Europe Infectious Disease Diagnostics Market (by Infectious Disease Type)
- Figure 55: Europe Infectious Disease Diagnostics Market (by Infectious Diseases Type), $Million, 2020 and 2031
- Figure 56: Europe Infectious Disease Diagnostics Market (Bacterial Infectious Diseases), $Million, 2020-2031
- Figure 57: Europe Infectious Disease Diagnostics Market (Viral Infectious Diseases), $Million, 2020-2031
- Figure 58: Europe Infectious Disease Diagnostics Market (Fungal Infectious Diseases), $Million, 2020-2031
- Figure 59: Europe Infectious Disease Diagnostics Market (Other Infectious Diseases), $Million, 2020-2031
- Figure 60: Europe Infectious Disease Diagnostics Market (by Infection Type)
- Figure 61: Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 and 2031
- Figure 62: Europe Infectious Disease Diagnostics Market (Respiratory Infections), $Million, 2020-2031
- Figure 63: Europe Infectious Disease Diagnostics Market (COVID-19 Infection, by Respiratory Infections), $Million, 2020-2031
- Figure 64: Europe Infectious Disease Diagnostics Market (Influenza A and B, by Respiratory Infections), $Million, 2020-2031
- Figure 65: Europe Infectious Disease Diagnostics Market (Respiratory Syncytial Virus, by Respiratory Infections), $Million, 2020-2031
- Figure 66: Europe Infectious Disease Diagnostics Market (Mycoplasma Infections, by Respiratory Infections), $Million, 2020-2031
- Figure 67: Europe Infectious Disease Diagnostics Market (Pertussis Infections, by Respiratory Infections), $Million, 2020-2031
- Figure 68: Europe Infectious Disease Diagnostics Market (Other Respiratory Infections, by Respiratory Infections), $Million, 2020-2031
- Figure 69: Europe Infectious Disease Diagnostics Market (Hospital-Acquired Infections (HAIs)), $Million, 2020-2031
- Figure 70: Europe Infectious Disease Diagnostics Market (Sexually Transmitted Infections), $Million, 2020-2031
- Figure 71: Europe Infectious Disease Diagnostics Market (Hepatitis B, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 72: Europe Infectious Disease Diagnostics Market (HIV-AIDS, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 73: Europe Infectious Disease Diagnostics Market (Human Papillomavirus (HPV), by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 74: Europe Infectious Disease Diagnostics Market (Neisseria Gonorrhea, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 75: Europe Infectious Disease Diagnostics Market (Other STIs, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 76: Europe Infectious Disease Diagnostics Market (Other Infections), $Million, 2020-2031
- Figure 77: Europe Infectious Disease Diagnostics Market (by End User)
- Figure 78: Share of Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 and 2031
- Figure 79: Europe Infectious Disease Diagnostics Market (Hospitals), $Million, 2020-2031
- Figure 80: Europe Infectious Disease Diagnostics Market (Hospitals, by Respiratory Infections), $Million, 2020-2031
- Figure 81: Europe Infectious Disease Diagnostics Market (Hospitals, Influenza A and B), $Million, 2020-2031
- Figure 82: Europe Infectious Disease Diagnostics Market (Hospitals, COVID-19 Infection), $Million, 2020-2031
- Figure 83: Europe Infectious Disease Diagnostics Market (Hospitals, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
- Figure 84: Europe Infectious Disease Diagnostics Market (Hospitals, Mycoplasma Infections), $Million, 2020-2031
- Figure 85: Europe Infectious Disease Diagnostics Market (Hospitals, Pertussis Infections), $Million, 2020-2031
- Figure 86: Europe Infectious Disease Diagnostics Market (Hospitals, Other Respiratory Infections), $Million, 2020-2031
- Figure 87: Europe Infectious Disease Diagnostics Market By (Hospitals, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 88: Europe Infectious Disease Diagnostics Market (Hospitals, Hepatitis B), $Million, 2020-2031
- Figure 89: Europe Infectious Disease Diagnostics Market (Hospitals, HIV-AIDS), $Million, 2020-2031
- Figure 90: Europe Infectious Disease Diagnostics Market (Hospitals, HPV), $Million, 2020-2031
- Figure 91: Europe Infectious Disease Diagnostics Market (Hospitals, Neisseria Gonorrhea), $Million, 2020-2031
- Figure 92: Europe Infectious Disease Diagnostics Market (Hospitals, Other STIs), $Million, 2020-2031
- Figure 93: Europe Infectious Disease Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
- Figure 94: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Respiratory Infections) $Million, 2020-2031
- Figure 95: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Influenza A and B), $Million, 2020-2031
- Figure 96: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, COVID-19 Infection), $Million, 2020-2031
- Figure 97: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Respiratory Syncytial Virus), $Million, 2020-2031
- Figure 98: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Mycoplasma Infections), $Million, 2020-2031
- Figure 99: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Pertussis Infections), $Million, 2020-2031
- Figure 100: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other Respiratory Infections), $Million, 2020-2031
- Figure 101: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 102: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Hepatitis B), $Million, 2020-2031
- Figure 103: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HIV-AIDS), $Million, 2020-2031
- Figure 104: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HPV), $Million, 2020-2031
- Figure 105: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Neisseria Gonorrhea), $Million, 2020-2031
- Figure 106: Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other STIs), $Million, 2020-2031
- Figure 107: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
- Figure 108: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Infections), $Million, 2020-2031
- Figure 109: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Influenza A and B), $Million, 2020-2031
- Figure 110: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, COVID-19 Infection), $Million, 2020-2031
- Figure 111: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
- Figure 112: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Mycoplasma Infections), $Million, 2020-2031
- Figure 113: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Pertussis Infections), $Million, 2020-2031
- Figure 114: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other Respiratory Infections), $Million, 2020-2031
- Figure 115: Europe Infectious Disease Diagnostics Market By (Out-Patient Clinics/General Practitioners, by Sexually Transmitted Infections), $Million, 2020-2031
- Figure 116: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Hepatitis B), $Million, 2020-2031
- Figure 117: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HIV-AIDS), $Million, 2020-2031
- Figure 118: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HPV), $Million, 2020-2031
- Figure 119: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Neisseria Gonorrhea), $Million, 2020-2031
- Figure 120: Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other STIs), $Million, 2020-2031
- Figure 121: Europe Infectious Disease Diagnostics Market (Research Laboratories), $Million, 2020-2031
- Figure 122: Europe Infectious Disease Diagnostics Market (Research Laboratories, by Respiratory Infections), Respiratory Infections, $Million, 2020-2031
- Figure 123: Europe Infectious Disease Diagnostics Market (Research Laboratories, Influenza A and B), $Million, 2020-2031
- Figure 124: Europe Infectious Disease Diagnostics Market (Research Laboratories COVID-19 Infection), $Million, 2020-2031
- Figure 125: Europe Infectious Disease Diagnostics Market (Research Laboratories, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
- Figure 126: Europe Infectious Disease Diagnostics Market (Research Laboratories, Mycoplasma Infections), $Million, 2020-2031
- Figure 127: Europe Infectious Disease Diagnostics Market (Research Laboratories, Pertussis Infections), $Million, 2020-2031
- Figure 128: Europe Infectious Disease Diagnostics Market (Research Laboratories, Other Respiratory Infections), $Million, 2020-2031
- Figure 129: Europe Infectious Disease Diagnostics Market (Research Laboratories, Sexually Transmitted Infections), $Million, 2020-2031
- Figure 130: Europe Infectious Disease Diagnostics Market (Research Laboratories, Hepatitis B), $Million, 2020-2031
- Figure 131: Europe Infectious Disease Diagnostics Market (Research Laboratories, HIV-AIDS), $Million, 2020-2031
- Figure 132: Europe Infectious Disease Diagnostics Market (Research Laboratories, HPV), $Million, 2020-2031
- Figure 133: Europe Infectious Disease Diagnostics Market (Research Laboratories, Neisseria Gonorrhea), $Million, 2020-2031
- Figure 134: Europe Infectious Disease Diagnostics Market (Research Laboratories, Other STIs), $Million, 2020-2031
- Figure 135: Europe Infectious Disease Diagnostics Market (Other End Users), $Million, 2020-2031
- Figure 136: Europe Infectious Disease Diagnostics Market (by Region), $Million, 2020-2031
- Figure 137: Europe Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031
- Figure 138: Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 139: Europe: Market Dynamics
- Figure 140: Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 and 2031
- Figure 141: Germany Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 142: Germany Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
- Figure 143: U.K. Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 144: U.K. Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
- Figure 145: France Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 146: France Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
- Figure 147: Italy Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 148: Italy Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
- Figure 149: Spain Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 150: Spain Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
- Figure 151: Baltic Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031
- Figure 152: Baltic Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 153: Baltic: Market Dynamics
- Figure 154: Estonia Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 155: Lithuania Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 156: Latvia Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 157: Nordic Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 158: Denmark Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 159: Sweden Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 160: Norway Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 161: Finland Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 162: Rest-of-Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
- Figure 163: Rest-of-Europe Infectious Disease Diagnostics Market, Thousand Unit, 2020-2031
- Figure 164: Share of Key Companies Profiled
- Figure 165: Abbott: Product Portfolio
- Figure 166: Abbott: Overall Financials, $Million, 2019-2021
- Figure 167: Abbott: Revenue (by Segment), $Million, 2019-2021
- Figure 168: Abbott: Revenue (by Region), $Million, 2019-2021
- Figure 169: Abbott: R&D Expenditure, $Million, 2019-2021
- Figure 170: Abbott: SWOT Analysis
- Figure 171: Agilent Technologies, Inc.: Product Portfolio
- Figure 172: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
- Figure 173: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 174: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 175: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 176: Agilent Technologies, Inc.: SWOT Analysis
- Figure 177: Becton, Dickinson and Company (BD): Product Portfolio
- Figure 178: Becton, Dickinson and Company (BD): Overall Financials, $Million, 2019-2021
- Figure 179: Becton, Dickinson and Company (BD): Revenue (by Segment), $Million, 2019-2021
- Figure 180: Becton, Dickinson and Company (BD): Revenue (by Region), $Million, 2019-2021
- Figure 181: Becton, Dickinson and Company (BD): R&D Expenditure, $Million, 2019-2021
- Figure 182: Becton, Dickinson and Company: SWOT Analysis
- Figure 183: bioMérieux SA: Product Portfolio
- Figure 184: bioMérieux SA: Overall Financials, $Million, 2019-2021
- Figure 185: bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
- Figure 186: bioMérieux SA: Revenue (by Region), $Million, 2019-2021
- Figure 187: bioMérieux SA: R&D Expenditure, $Million, 2019-2021
- Figure 188: bioMérieux SA: SWOT Analysis
- Figure 189: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 190: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
- Figure 191: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 192: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 193: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 194: Bio-Rad Laboratories, Inc.: SWOT Analysis
- Figure 195: Danaher: Product Portfolio
- Figure 196: Danaher: Overall Financials, $Million, 2019-2021
- Figure 197: Danaher: Revenue (by Segment), $Million, 2019-2021
- Figure 198: Danaher: Revenue (by Region), $Million, 2019-2021
- Figure 199: Danaher: R&D Expenditure, $Million, 2019-2021
- Figure 200: Danaher: SWOT Analysis
- Figure 201: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 202: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
- Figure 203: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
- Figure 204: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2018-2020
- Figure 205: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
- Figure 206: F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 207: Illumina, Inc.: Product Portfolio
- Figure 208: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 209: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 210: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 211: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 212: Illumina, Inc.: SWOT Analysis
- Figure 213: QIAGEN N.V.: Product Portfolio
- Figure 214: QIAGEN N.V.: Overall Financials, $Million, 2018-2020
- Figure 215: QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
- Figure 216: QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
- Figure 217: QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
- Figure 218: QIAGEN N.V.: SWOT Analysis
- Figure 219: Siemens Healthcare GmbH: Product Portfolio
- Figure 220: Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021
- Figure 221: Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021
- Figure 222: Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021
- Figure 223: Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021
- Figure 224: Siemens Healthcare GmbH: SWOT Analysis
- Figure 225: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 226: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
- Figure 227: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 228: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 229: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 230: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 231: PerkinElmer Inc.: Product Portfolio
- Figure 232: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
- Figure 233: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 234: PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 235: PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 236: PerkinElmer, Inc.: SWOT Analysis
- Figure 237: Hologic Inc. (Mobidiag Ltd.): Product Portfolio
- Figure 238: Hologic Inc. (Mobidiag Ltd.): Overall Financials, $Million, 2019-2021
- Figure 239: Hologic Inc. (Mobidiag Ltd.): Revenue (by Segment), $Million, 2019-2021
- Figure 240: Hologic Inc. (Mobidiag Ltd.): Revenue (by Region), $Million, 2019-2021
- Figure 241: Hologic Inc. (Mobidiag Ltd.): R&D Expenditure, $Million, 2019-2021
- Figure 242: Hologic Inc. (Mobidiag Ltd.): SWOT Analysis
- Figure 243: Abacus Diagnostica Oy: Product Portfolio
- Figure 244: Abacus Diagnostica Oy: SWOT Analysis
- Figure 245: Novacyt Group.: Product Portfolio
- Figure 246: Novacyt Group.: Overall Financials, $Million, 2018-2020
- Figure 247: Novacyt Group.: Revenue (by Segment), $Million, 2018-2020
- Figure 248: Novacyt Group.: R&D Expenditure, $Million, 2018-2020
- Figure 249: Novacyt Group.: SWOT Analysis
- Figure 250: Biocartis: Product Portfolio
- Figure 251: Biocartis: SWOT Analysis
- List of Tables
- Table 1: COVID-19 Impact on Europe Infectious Disease Diagnostics Market
- Table 2: Products Launched by Various Manufacturers for Infectious Disease Diagnostics Research
- Table 3: Companies Providing System
- Table 4: Companies Providing Kits and Reagents
- Table 5: Companies Providing Software
- Table 6: PCR-Based Infectious Diagnostics Products
- Table 7: NGS-Based Infectious Diagnostics Products
- Table 8: Key Players Offering Infectious Diagnostics in the U.K.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook